B.Riley Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/7/2026
- US stocks gain as surprise payrolls fall quells rate-hike fears
- US nonfarm payrolls unexpectedly decline in July; unemployment rate eases to 4.1%
- Oil prices drop as investors weigh potential Hormuz deal between Iran and Gulf states
- Atlassian results seen as 'game changer' for AI kills software worries
- The Trade Desk hit by Wall St downgrades after disappointing Q2 results, outlook
- Trump held multiple undisclosed calls with Fed Chair Warsh, reports say
- Stocks close lower as investors eye Mideast talks, earnings
- Apollo to acquire easyJet for £5.7B in cash deal
- The Trade Desk Inc. (TTD) Tops Q2 EPS by 16c, Misses on Revenue; Offers Weak Q3 Revenue Guidance
- Nielsen to acquire DoubleVerify in merger deal
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Denali Therapeutics Inc. (DNLI) PT Raised to $29 at BofA Securities
September 3, 2024 11:47 AM EDT(Updated - September 4, 2024 5:26 AM EDT)
BofA Securities analyst Tazeen Ahmad raised the price target on Denali Therapeutics Inc. (NASDAQ: DNLI) to $29.00 (from $25.00) while maintaining a Buy rating.
The analyst comments "After meeting with FDA, Denali (DNLI) has reached alignment with... More
Goldman Sachs Reiterates Buy Rating on Denali Therapeutics Inc. (DNLI)
September 3, 2024 11:46 AM EDTGoldman Sachs analyst Salveen Richter reiterated a Buy rating and $46.00 price target on Denali Therapeutics Inc. (NASDAQ: DNLI).
The analyst comments "DNLI announced that it has reached alignment with the FDA on an accelerated pathway (i.e., that cerebrospinal fluid heparan sulfate can be used as a surrogate endpoint to support accelerated approval) and subsequent conversion to full approval for... More
Stifel Reiterates Hold Rating on Denali Therapeutics Inc. (DNLI)
September 3, 2024 10:22 AM EDTStifel analyst Paul Mattels reiterated a Hold rating and $22.00 price target on Denali Therapeutics Inc. (NASDAQ: DNLI)
The analyst comments "DNLI announced a recent successful meeting with FDA's CDER has provided a path to filing for accelerated approval of DNL310 in Hunter--filing... More
Denali Therapeutics (DNLI) Announces Successful Meeting with the FDA, Plans to File for Accelerated Approval of Tividenofusp Alfa
September 3, 2024 8:02 AM EDTDenali Therapeutics Inc. (Nasdaq: DNLI) today announced the outcome of a recent successful meeting with the Center for Drug Evaluation and Research (CDER) division of the U.S. Food and Drug Administration (FDA) providing a path to filing a biologics license application (BLA) for accelerated approval and subsequent conversion to full approval for tividenofusp alfa (DNL310) for the treatment of MPS II (Hunter syndrome). Agreement was reached that cerebrospinal fluid heparan sulfate (CSF HS) is reasonably likely to predict clinical benefit and can be used as a surrogate endpoint to support accelerated... More
